Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Non-Hodgkin Lymphoma: early-phase trial registry
12 of 18 indexed Refractory Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 12 currently recruiting · #953 of 28,707 conditions by registered trial count
Refractory Non-Hodgkin Lymphoma: 18 US clinical trials tracked, 12 recruiting.
Refractory Non-Hodgkin Lymphoma is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Lyell Immunopharma, running 2 of these trials.
Enrollment posture brief
Registry condition refractory-non-hodgkin-lymphoma
OPEN 12 | RECR 67% | LATE 1 | EARLY 17 | RANK #953 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Refractory Non-Hodgkin Lymphoma lists 12 open slots (67% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Non-Hodgkin Lymphoma is recruiting above its size-band peers.
12 of 18 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Refractory Non-Hodgkin Lymphoma trials is spread across many organizations.
Lyell Immunopharma accounts for 2 of 18 trials (11.1%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 28 among the 18 trials that report a genuine target (sentinel values excluded). 13 of those (72.2%) plan for fewer than 100 participants.
-
Refractory Non-Hodgkin Lymphoma research is mostly interventional.
18 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Lyell Immunopharma
NCT07188558
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma
NCT05826535
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics
NCT06119685
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
NCT05892718
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Marcela V. Maus, M.D.,Ph.D.
NCT06550141
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
SIRPant Immunotherapeutics
NCT05967416
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Rita Assi
NCT06484920
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Marcela V. Maus, M.D.,Ph.D.
NCT06026319
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Lazaros Lekakis
NCT05260957
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Estrella Biopharma
NCT06343311
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
NCT06544265
9-ING-41 in Patients with Advanced Cancers
Actuate Therapeutics
NCT03678883
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
NCT05828589
Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma
University of Nebraska
NCT05621096
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
University of Washington
NCT01703949
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
Paolo Caimi, MD
NCT05053659
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
NCT04640779
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Non-Hodgkin Lymphoma page
18 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Refractory Non-Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Lyell Immunopharma sponsors the most Refractory Non-Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See Lyell Immunopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Non-Hodgkin Lymphoma condition card totals 18 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.